Kalos Therapeutics Signs Letter of Intent with Oncology Pharma

Kalos Therapeutics is developing a platform of drugs containing multiple arrays of natriuretic peptide which have demonstrated a broad spectrum of anti-tumor activity with negligible or no known adverse effects.

In a Pre-IND Study using the parent drug involving a total of eighty-eight patients, including 22 healthy patients, the study demonstrated safety and therapeutic efficacy. Kalos’s leading drug candidate, KTH 222, regulates cell growth via inhibition of the mitogen-activated protein kinase (MAPK) pathway. Kalos is looking to change the care paradigm for treating cancer patients as KTH 222 can be a lead therapy, or used in combination with existing therapies to improve efficacy and reduce toxicity, and mitigate resistance or reverse it. There are nearly 17 million patients living with a cancer diagnosis without a safe non-toxic maintenance therapy; Kalos believes it will attain this lofty goal and become the Holy Grail for “cancer tune-up,” and a therapeutic option to a drug Holiday.

In August of 2019, Oncology Pharma (OTCPK: ONPH)  announced that it signed a Letter of Intent with Kalos for a worldwide license and co-development of Kalos’s lead anti-cancer drug, KTH 222. The expected license and co-development of KTH 222 as a monotherapy and/or in combination with NanoSmart’s ANA-conjugated liposomal doxorubicin targeted delivery is licensed exclusively worldwide by Oncology Pharma. Doxorubicin is one of the most commonly used chemotherapies for treating a wide variety of cancers such as breast, ovarian, lung, bladder, lymphoma, and Kaposi’s sarcoma. The KTH 222 combined with the NanoSmart’s targeted delivery of doxorubicin provides an excellent synergy between the two therapies while offsetting further the potential cardiotoxicity inherent with doxorubicin.   

Kalos  Therapeutics, Inc. CEO, George Colberg, announced in a statement, “The collaboration with the Oncology Pharma has provided new opportunities for Kalos to advance its drug development program changing how cancer patients can be treated with safer, nontoxic approaches improving the patient’s quality of life. The possibility of bringing to market a safer more promising version of the Oncology Pharma product line is extremely exciting!”

Kalos is devoted to treating the unmet needs of people living with incurable diseases while doing so with less toxic and debilitating side effects commonly associated with chemotherapies. The company  believes that by leveraging nature and all of the body’s mechanisms, they have created new, safer approaches to cancer and diseases that affect the eye as well.  Kalos has several applications for animal health based on both its 8 amino acid and a 15 amino acid drug KTV-111.

Kalos aims to treat dangerous and debilitating diseases and improve the quality of life for the patient and their families.

Oncology Pharma describes itself as a pioneering oncology company dedicated to developing, manufacturing, and commercializing therapeutics. The company has licensed Tulynode’s patent-pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. The company is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Oncology Pharma in the forefront of developing technologies in cancer research, biotechnology, and healthcare.

Posted in AZBio News.